Clinical trials: Leucovorin
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate
- Trial name
- CAPT-02 (NCT06172036)
- Testing
- irinotecan liposome + oxaliplatin + 5-FU / LV, Adebellizumab
- Volunteers
- 180 people
- Sponsor
- Zhejiang University
Advanced Colorectal Cancer
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
The ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment…
- Trial name
- ONTOP (NCT07106034)
- Testing
- Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Pudong Hospital
Rectal Cancer, Metastatic
Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT03022734
- Testing
- chemotherapy, radiotherapy
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Autism Spectrum Disorder
Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder
No such study has been conducted in Pakistan so the primary objective of this study was to determine the role of folinic acid in improving the speech and adaptive skills while secondary objective was improvement of stereotype…
- Trial name
- NCT05013164
- Testing
- Folinic Acid
- Where
- Pakistan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Nishtar Medical University
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02620865
- Testing
- Aldesleukin, Antibody Therapy, Fluorouracil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Colorectal Cancer
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- QUATTRO-II (NCT04097444)
- Testing
- Bevacizumab, 5-fluorouracil, Leucovorin calcium
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Chugai Pharmaceutical
Advanced Relapsed Tumors, Refractory Solid Tumors
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
- Trial name
- NCT02482441
- Testing
- OMP-131R10, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Rectal Neoplasms, Adenocarcinoma
Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer
The current standard treatment of locally advanced rectal cancer (clinical stage II or III) is preoperative radiation with chemotherapy (CRT) followed by surgery.
- Trial name
- PREPARE (NCT01952951)
- Testing
- Capecitabine Oxaliplatin, pelvic radiation capecitabine 5-fluorouracil
- Where
- 7 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- National Cancer Center, Korea
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
This is a phase Ⅱ clinical study of Zanubrutinib(Z) in combination with methotrexate (M) and thiotepa(T) in treating newly diagnosed primary CNS lymphoma (PCNSL).
- Trial name
- NCT06646211
- Testing
- Zanubrutinib , Thiotepa, Methotrexate , Thiotepa and Zanubrutinib, ASCT±Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 104 sites in United States, Brazil and 9 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Peripheral Neuropathy
Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy
The purpose of this study is to estimate the usefulness and safety of HD6610 granule for oxaliplatin-induced peripheral neuropathy.
- Trial name
- NCT02590367
- Testing
- FOLFOX regimen, HD6610 Granule
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Jiangsu Province Hospital of Traditional Chinese Medicine
Stage I Colon Cancer, Stage II Colon Cancer
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
This is a Phase II open-label trial of neoadjuvant immunochemotherapy with Atezolizumab and CAPOX followed by surgery and potentially adjuvant chemotherapy for patients with localized resectable pMMR adenocarcinoma of the colon…
- Conditions
- Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Trial name
- NICER (NCT05870800)
- Testing
- Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Rectal Cancer Recurrent
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over…
- Trial name
- JCOG1801 (NCT04288999)
- Testing
- Chemotherapy, Preoperative radiotherapy, Procedure
- Where
- 45 sites in Japan
- Volunteers
- 110 people
- Sponsor
- National Cancer Center Hospital East
Colon Cancer
FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
This project consists of two independent, following specific eligibility criteria and different randomisation schemes studies, later on called DURATION study and BEV study.
- Trial name
- TOSCA (NCT00646607)
- Testing
- FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
- Where
- 111 sites in Italy
- Volunteers
- 3,756 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
ctDNA, Chemotherapy
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Chemotherapy, Colorectal Cancer
- Trial name
- CLEAR-02 (NCT07562711)
- Testing
- Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab.
- Trial name
- Toco-CoR (NCT04245865)
- Testing
- Fluorouracil, Calcium folinate, Oxaliplatin
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- Vejle Hospital
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.